Cancer Research The Future of Cancer Research: Science and Patient Impact AACR Conference on Molecular Diagnostics - 2008
HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
Cancer Research Clinical Cancer Research
Cancer Epidemiology Biomarkers & Prevention Molecular Cancer Therapeutics
Molecular Cancer Research Cancer Prevention Research
Cancer Prevention Journals Portal Cancer Reviews Online
Annual Meeting Education Book Meeting Abstracts Online
This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrow reprints & permissions
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Shipman, C. M.
Right arrow Articles by Croucher, P. I.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Shipman, C. M.
Right arrow Articles by Croucher, P. I.
[Cancer Research 63, 912-916, March 1, 2003]
© 2003 American Association for Cancer Research

Advances in Brief

Osteoprotegerin Is a Soluble Decoy Receptor for Tumor Necrosis Factor-related Apoptosis-inducing Ligand/Apo2 Ligand and Can Function as a Paracrine Survival Factor for Human Myeloma Cells1

Claire M. Shipman2 and Peter I. Croucher

Nuffield Department of Orthopaedic Surgery, University of Oxford, Nuffield Orthopaedic Center, Oxford OX3 7LD, United Kingdom

Myeloma cells grow only in the bone marrow closely associated with bone,suggesting that this microenvironment provides critical signals for their growth and survival. Osteoprotegerin (OPG) is a member of the tumor necrosis factor (TNF) receptor family, which binds to the ligand for receptor activator of nuclear factor {kappa}B and inhibits bone resorption. However, it is unclear whether OPG can also bind to other TNF family members, such as TNF-related apoptosis-inducing ligand/Apo2 ligand (TRAIL/Apo2L), and, by inhibiting their activity, function as a survival factor for myeloma cells. In the present study MG63 osteoblast-like cells and primary bone marrow stromal cells were both shown to produce OPG, whereas human myeloma cells did not produce OPG but down-regulated release of OPG from MG63 cells. TRAIL/Apo2L induced apoptosis in myeloma cells, and this could be prevented with the addition of recombinant OPG. Medium conditioned by MG63 cells was also shown to inhibit TRAIL/Apo2L-induced apoptosis, an effect that was reversed by the addition of soluble receptor activator of nuclear factor {kappa}B ligand. Medium conditioned by cocultures of MG63 cells with myeloma cells had a reduced effect on TRAIL/Apo2L-induced apoptosis, reflecting the decreased concentrations of OPG in cocultures of myeloma cells with bone cells. These observations suggest that OPG may function as a paracrine survival factor in the bone marrow microenvironment in multiple myeloma.




This article has been cited by other articles:


Home page
 BloodHome page
Y.-W. Qiang, J. D. Shaughnessy Jr, and S. Yaccoby
Wnt3a signaling within bone inhibits multiple myeloma bone disease and tumor growth
Blood, July 15, 2008; 112(2): 374 - 382.
[Abstract] [Full Text] [PDF]

Home page
 Endocr. Rev.Home page
A. E. Kearns, S. Khosla, and P. J. Kostenuik
Receptor Activator of Nuclear Factor {kappa}B Ligand and Osteoprotegerin Regulation of Bone Remodeling in Health and Disease
Endocr. Rev., April 1, 2008; 29(2): 155 - 192.
[Abstract] [Full Text] [PDF]

Home page
 BloodHome page
P. Secchiero, F. Corallini, E. Rimondi, C. Chiaruttini, M. G. di Iasio, A. Rustighi, G. Del Sal, and G. Zauli
Activation of the p53 pathway down-regulates the osteoprotegerin expression and release by vascular endothelial cells
Blood, February 1, 2008; 111(3): 1287 - 1294.
[Abstract] [Full Text] [PDF]

Home page
 Molecular Cancer TherapeuticsHome page
R. M. Locklin, E. Federici, B. Espina, P. A. Hulley, R. G. G. Russell, and C. M. Edwards
Selective targeting of death receptor 5 circumvents resistance of MG-63 osteosarcoma cells to TRAIL-induced apoptosis
Mol. Cancer Ther., December 1, 2007; 6(12): 3219 - 3228.
[Abstract] [Full Text] [PDF]

Home page
 J. Biol. Chem.Home page
S. Vitovski, J. S. Phillips, J. Sayers, and P. I. Croucher
Investigating the Interaction between Osteoprotegerin and Receptor Activator of NF-{kappa}B or Tumor Necrosis Factor-related Apoptosis-inducing Ligand: EVIDENCE FOR A PIVOTAL ROLE FOR OSTEOPROTEGERIN IN REGULATING TWO DISTINCT PATHWAYS
J. Biol. Chem., October 26, 2007; 282(43): 31601 - 31609.
[Abstract] [Full Text] [PDF]

Home page
 BloodHome page
G. Zauli, F. Corallini, F. Bossi, F. Fischetti, P. Durigutto, C. Celeghini, F. Tedesco, and P. Secchiero
Osteoprotegerin increases leukocyte adhesion to endothelial cells both in vitro and in vivo
Blood, July 15, 2007; 110(2): 536 - 543.
[Abstract] [Full Text] [PDF]

Home page
 BloodHome page
N. Giuliani, F. Morandi, S. Tagliaferri, M. Lazzaretti, S. Bonomini, M. Crugnola, C. Mancini, E. Martella, L. Ferrari, A. Tabilio, et al.
The proteasome inhibitor bortezomib affects osteoblast differentiation in vitro and in vivo in multiple myeloma patients
Blood, July 1, 2007; 110(1): 334 - 338.
[Abstract] [Full Text] [PDF]

Home page
 Cancer Res.Home page
D. J. Heath, K. Vanderkerken, X. Cheng, O. Gallagher, M. Prideaux, R. Murali, and P. I. Croucher
An Osteoprotegerin-like Peptidomimetic Inhibits Osteoclastic Bone Resorption and Osteolytic Bone Disease in Myeloma
Cancer Res., January 1, 2007; 67(1): 202 - 208.
[Abstract] [Full Text] [PDF]

Home page
 BloodHome page
N. Giuliani, V. Rizzoli, and G. D. Roodman
Multiple myeloma bone disease: pathophysiology of osteoblast inhibition
Blood, December 15, 2006; 108(13): 3992 - 3996.
[Abstract] [Full Text] [PDF]

Home page
 Clin. Cancer Res.Home page
H. S. Yeh and J. R. Berenson
Treatment for myeloma bone disease.
Clin. Cancer Res., October 15, 2006; 12(20): 6279s - 6284s.
[Abstract] [Full Text] [PDF]

Home page
 Clin. Cancer Res.Home page
R. L. Vessella and E. Corey
Targeting factors involved in bone remodeling as treatment strategies in prostate cancer bone metastasis.
Clin. Cancer Res., October 15, 2006; 12(20): 6285s - 6290s.
[Abstract] [Full Text] [PDF]

Home page
 Mult SclerHome page
B. Weinstock-Guttman, J. Hong, R. Santos, M. Tamano-Blanco, D. Badgett, K. Patrick, M. Baier, J. Feichter, E. Gallagher, N. Garg, et al.
Interferon-{beta} modulates bone-associated cytokines and osteoclast precursor activity in multiple sclerosis patients
Multiple Sclerosis, September 1, 2006; 12(5): 541 - 550.
[Abstract] [PDF]

Home page
 BloodHome page
E. Menoret, P. Gomez-Bougie, A. Geffroy-Luseau, S. Daniels, P. Moreau, S. Le Gouill, J.-L. Harousseau, R. Bataille, M. Amiot, and C. Pellat-Deceunynck
Mcl-1L cleavage is involved in TRAIL-R1- and TRAIL-R2-mediated apoptosis induced by HGS-ETR1 and HGS-ETR2 human mAbs in myeloma cells
Blood, August 15, 2006; 108(4): 1346 - 1352.
[Abstract] [Full Text] [PDF]

Home page
 J. Clin. Pathol.Home page
C Van Poznak, S S Cross, M Saggese, C Hudis, K S Panageas, L Norton, R E Coleman, and I Holen
Expression of osteoprotegerin (OPG), TNF related apoptosis inducing ligand (TRAIL), and receptor activator of nuclear factor {kappa}B ligand (RANKL) in human breast tumours
J. Clin. Pathol., January 1, 2006; 59(1): 56 - 63.
[Abstract] [Full Text] [PDF]

Home page
 GutHome page
A J Ashcroft and S R Carding
RANK ligand and osteoprotegerin: emerging roles in mucosal inflammation
Gut, September 1, 2005; 54(9): 1345 - 1346.
[Full Text] [PDF]

Home page
 CirculationHome page
C. S. Moran, M. McCann, M. Karan, P. Norman, N. Ketheesan, and J. Golledge
Association of Osteoprotegerin With Human Abdominal Aortic Aneurysm Progression
Circulation, June 14, 2005; 111(23): 3119 - 3125.
[Abstract] [Full Text] [PDF]

Home page
 BloodHome page
R. N. Pearse, S. L. Swendeman, Y. Li, D. Rafii, and B. L. Hempstead
A neurotrophin axis in myeloma: TrkB and BDNF promote tumor-cell survival
Blood, June 1, 2005; 105(11): 4429 - 4436.
[Abstract] [Full Text] [PDF]

Home page
 Clin. Cancer Res.Home page
T. Yamamoto, H. Nagano, M. Sakon, H. Wada, H. Eguchi, M. Kondo, B. Damdinsuren, H. Ota, M. Nakamura, H. Wada, et al.
Partial Contribution of Tumor Necrosis Factor-Related Apoptosis-Inducing Ligand (TRAIL)/TRAIL Receptor Pathway to Antitumor Effects of Interferon-{alpha}/5-Fluorouracil against Hepatocellular Carcinoma
Clin. Cancer Res., December 1, 2004; 10(23): 7884 - 7895.
[Abstract] [Full Text] [PDF]

Home page
 BloodHome page
S. Colucci, G. Brunetti, R. Rizzi, A. Zonno, G. Mori, G. Colaianni, D. Del Prete, R. Faccio, A. Liso, S. Capalbo, et al.
T cells support osteoclastogenesis in an in vitro model derived from human multiple myeloma bone disease: the role of the OPG/TRAIL interaction
Blood, December 1, 2004; 104(12): 3722 - 3730.
[Abstract] [Full Text] [PDF]

Home page
 Hum ReprodHome page
M. Harada, Y. Osuga, T. Hirata, Y. Hirota, K. Koga, O. Yoshino, C. Morimoto, T. Fujiwara, M. Momoeda, T. Yano, et al.
Concentration of osteoprotegerin (OPG) in peritoneal fluid is increased in women with endometriosis
Hum. Reprod., October 1, 2004; 19(10): 2188 - 2191.
[Abstract] [Full Text] [PDF]

Home page
 Cancer Res.Home page
J. Zhang, J. Dai, Z. Yao, Y. Lu, W. Dougall, and E. T. Keller
Soluble Receptor Activator of Nuclear Factor {kappa}B Fc Diminishes Prostate Cancer Progression in Bone
Cancer Res., November 15, 2003; 63(22): 7883 - 7890.
[Abstract] [Full Text] [PDF]

Home page
 Cancer Res.Home page
A. N. Farrugia, G. J. Atkins, L. B. To, B. Pan, N. Horvath, P. Kostakis, D. M. Findlay, P. Bardy, and A. C. W. Zannettino
Receptor Activator of Nuclear Factor-{kappa}B Ligand Expression by Human Myeloma Cells Mediates Osteoclast Formation in Vitro and Correlates with Bone Destruction in Vivo
Cancer Res., September 1, 2003; 63(17): 5438 - 5445.
[Abstract] [Full Text] [PDF]

Home page
 ASH Education BookHome page
S. Barille-Nion, B. Barlogie, R. Bataille, P. L. Bergsagel, J. Epstein, R. G. Fenton, J. Jacobson, W. M. Kuehl, J. Shaughnessy, and G. Tricot
Advances in Biology and Therapy of Multiple Myeloma
Hematology, January 1, 2003; 2003(1): 248 - 278.
[Abstract] [Full Text] [PDF]


HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
Cancer Research Clinical Cancer Research
Cancer Epidemiology Biomarkers & Prevention Molecular Cancer Therapeutics
Molecular Cancer Research Cancer Prevention Research
Cancer Prevention Journals Portal Cancer Reviews Online
Annual Meeting Education Book Meeting Abstracts Online
Copyright © 2003 by the American Association for Cancer Research.